论文部分内容阅读
目的：探讨度洛西汀联合阿立哌唑治疗难治性抑郁症的临床疗效和安全性。方法将93例难治性抑郁症患者随机分为两组，研究组口服度洛西汀联合阿立哌唑治疗，对照组单用度洛西汀治疗，观察8周。采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗8周末研究组显效率59．1％、有效率77．3％，对照组分别为31．1％、42．2％，研究组显效率、有效率均显著高于对照组（χ2＝7．04、11．35，P＜0．01）。两组不良反应较轻微，发生率比较差异无显著性（P＞0．05）。结论度洛西汀联合阿立哌唑治疗难治性抑郁症起效快，疗效显著，安全性高，显著优于单用度洛西汀治疗。“,”Objective To explore the efficacy and safety of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression (TRD) .Meth-ods Ninety-three TRD patients were randomly divided into two groups ,research group (n=47) was trea-ted with oral duloxetine plus aripiprazol and control group (n=46) with single duloxetine for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week ,obvious effective and effective rate were respectively 59 .1% and 77 .3% in research and 31 .1% and 42 .2% in control group , the former was significantly than the latter (χ2 = 7 .04 ,11 .35 ;P0 .05) .Conclusion Duloxetine plus aripiprazol takes effect more rapidly and has an evident effect and higher safety compared with single duloxetine in the treatment of T RD .